SANOVO Trial: ORPATHYS plus TAGRISSO Improves PFS in First-Line EGFR-Mutant Lung Cancer
HCM sits 31% above its 52-week low of $9.77.
Summary
Positive Phase III SANOVO results show ORPATHYS plus TAGRISSO significantly improved progression-free survival in first-line EGFR-mutant lung cancer patients with MET overexpression, extending the combination's reach into the frontline setting.
Key Events · Product Development and Regulatory · HCM
-
SANOVO Phase III Meets Primary Endpoint
ORPATHYS plus TAGRISSO demonstrated statistically significant and clinically meaningful PFS improvement versus TAGRISSO alone in both high MET and ITT populations in treatment-naïve EGFR-mutant NSCLC.
-
First-Line Expansion Potential
The combination is currently approved in China only for post-progression patients; SANOVO data support regulatory submission for the first-line setting, significantly expanding the addressable patient population.
-
Encouraging Overall Survival Trend
OS, a secondary endpoint, showed very encouraging clinical benefit in both populations, with follow-up ongoing; data will be presented at a forthcoming medical meeting.
-
Trial Design and Scale
326 treatment-naïve patients with EGFR mutations (exon 19 del or L858R) and MET overexpression were randomized 1:1 to TAGRISSO plus ORPATHYS or placebo.
Analysis · HCM · Life Sciences
The SANOVO Phase III trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival for the ORPATHYS plus TAGRISSO combination versus TAGRISSO alone in treatment-naïve patients with MET-overexpressing EGFR-mutated NSCLC. This extends the combination's clinical value into the first-line setting, building on the SAFFRON and SACHI trials in pre-treated patients. The encouraging overall survival trend, though immature, adds further weight. This is a major step toward expanding the approved indication in China, where the combination is currently approved only for post-progression patients.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HCM was trading at $12.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $9.77 to $18.30. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.